Pre-Open Stock Movers 06/26: (MDCA) (VXRT) (GPS) Higher; (SHIP) (SOLY) (NKE) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Argus Reiterates Buy Rating on Nike (NKE) Following 4Q
June 30, 2020 7:26 AM EDTArgus analyst John Staszak reiterated a Buy rating and $115.00 price target on Nike (NYSE: NKE) following the company's 4Q earnings report. Nike reported fiscal 4Q20 revenue and EPS that missed estimates. Revenue of $6.3 billion. the consensus estimate had called for revenue of $7.3 billion. The adjusted... More
Altimmune (ALT) Reports First Patient Dosing in Phase 1b Clinical Trial of NasoShield
June 30, 2020 7:04 AM EDTAltimmune, Inc. (NASDAQ: ALT) today announced dosing of the first patient in the Companys Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. The NasoShield program is being developed under a contract with the Biomedical Advanced Research and Development Authority (BARDA), with a total potential value of $133.7 million if all options in the contract (HHSO100201600008C) are exercised.
NasoShield is the only single dose anthrax vaccine in development that is supported by BARDA, and has the potential to provide a significant improvement over the available two- and... More
